Inovio Pharmaceuticals

INOPhase 3

Inovio Pharmaceuticals is a trailblazer in the DNA medicine field, leveraging its SynCon® and CELLECTRA® platform to develop next-generation immunotherapies. The company has a diverse clinical pipeline targeting HPV-related conditions, cancer, and infectious diseases, with a significant milestone being the FDA's acceptance of its first Biologics License Application (BLA) for INO-3107 in RRP. With a strong history of collaboration with government, academic, and industry partners, Inovio is strategically positioned to advance its platform and bring novel, potentially transformative treatments to market.

Market Cap

$109.0M

Focus

BiologicsRNA & Gene TherapySmall Molecules

INO · Stock Price

USD 1.5841.98 (-96.37%)

Historical price data

AI Company Overview

Technology Platform

Proprietary DNA medicine platform combining SynCon® engineered plasmids with CELLECTRA® electroporation delivery to enable in vivo production of therapeutic proteins, eliciting targeted immune responses without viral vectors or chemical adjuvants.

Pipeline Snapshot

47 drugs in pipeline, 3 in Phase 3

Drug	Indication	Stage
VGX-3100 + Placebo	Cervical Dysplasia	Phase 3
VGX-3100 + Matched Placebo	Cervical Dysplasia	Phase 3
INO-4800 + Placebo	Coronavirus Infection	Phase 2/3
INO-4700 + Placebo + INO-4700	Middle East Respiratory Syndrome Coronavirus (MERS-CoV)	Phase 2
VGX-3100 + Imiquimod 5% Cream	Vulvar High Grade Squamous Intraepithelial Lesion (HSIL)	Phase 2

Funding History

Total raised: $192M

PIPE$150MUndisclosedJun 15, 2020

IPO$30MUndisclosedFeb 12, 2004

Series A$12MApax PartnersJun 15, 2003

Opportunities

The primary near-term opportunity is the potential first-ever U.S.

approval of a therapeutic DNA medicine with INO-3107 for RRP, which would validate the platform and generate initial revenue.

Long-term opportunities include expanding the platform into larger markets in oncology (e.g., as a combination therapy) and infectious diseases, leveraging the platform's speed and versatility for pandemic preparedness, and securing additional strategic partnerships.

Risk Factors

Key risks include regulatory rejection or delay for INO-3107, failure of other pipeline candidates in clinical trials, challenges in commercializing a novel device-mediated therapy, significant ongoing cash burn requiring dilutive financing, and intense competition from more established therapeutic modalities like mRNA vaccines and cell therapies.

Competitive Landscape

Inovio competes with large pharma and biotech companies across its focus areas. In HPV/cancer, competitors include Merck & Co. (Keytruda) and other immunotherapy developers. In infectious diseases, it faces giants like Pfizer, Moderna, and Novavax. Its main differentiation is its DNA platform's ability to drive potent T-cell responses and its potential manufacturing and stability advantages, though it trails mRNA platforms in commercial validation for vaccines.

Company Info

TypeTherapeutics

LocationUnited States

StagePhase 3

RevenuePre-revenue

Trading

TickerINO

ExchangeNASDAQ

Contact

inovio.com clinical.trials@inovio.com

Therapeutic Areas

HPV-related DiseasesOncologyInfectious Diseases

Sectors

Cell & Gene Therapy Immunotherapy / Immuno-Oncology

Partners

Advaccine Biopharmaceuticals Suzhou Co.ApolloBio CorporationAstraZenecaThe Bill & Melinda Gates FoundationCoalition for Epidemic Preparedness Innovations (CEPI)Coherus BiosciencesDefense Advanced Research Projects Agency (DARPA)Department of Defense (DOD)HIV Vaccines Trial NetworkIndiana UniversityInternational Vaccine Institute (IVI)Kaneka EurogentecNational Cancer Institute, National Institutes of HealthNational Institute of Allergy and Infectious DiseasesPlumbline Life SciencesRegeneron PharmaceuticalsRichter-Helm BioLogicsThermo Fisher ScientificUniversity of PennsylvaniaWalter Reed Army Institute of ResearchThe Wistar Institute

SIMILAR COMPANIES